Alpha Tau Medical Aktie News

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain -

Alpha Tau Medical is positioned for major catalysts in 2026, with its differentiated, tumor-agnostic Alpha DaRT technology gaining visibility and momentum. Pancreatic cancer and GBM readouts expected in 2H26 have the potential to be inflection points. At ~$550M market cap, a strong cash position, and multiple upcoming readouts, DRTS offers attractive upside as it approaches proof-of-concept in ...

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-cen...

- Initial module submission marks an important milestone in the pre-market approval process -  - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to execution of ReSTART pivotal study ( Re current S CC T reatment with A lpha DaRT R adiation T herapy), which i...

- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau's broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet ne...

-  Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study -

JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.

-  Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation -